Smith Mark Douglas

SEC Form 4 insider trading activity

Smith Mark Douglas has filed 4 SEC Form 4 filings (5 transaction rows) across 2 companies, including JAZZ, PHR, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.

On the most recent filing, Smith Mark Douglas is listed as Director at Jazz Pharmaceuticals plc. Inside the rolling window, Smith Mark Douglas reported no open-market purchases and 1 open-market sale totaling $267K in JAZZ.

Companies traded

Other insiders at JAZZ

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$267K

reported sales (SEC code S)

Companies

2

in the rolling window

Source
JAZZ
Smith Mark Douglas
Sale$267KJun 17SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Smith Mark Douglas made?

Smith Mark Douglas has filed 4 SEC Form 4 filings (5 transaction rows) across 2 companies, including JAZZ, PHR since 2026.

Which companies does Smith Mark Douglas trade?

Smith Mark Douglas has filed SEC Form 4 disclosures for 2 companies, including JAZZ, PHR.

When was Smith Mark Douglas's most recent SEC Form 4 filing?

Smith Mark Douglas's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.

What is Smith Mark Douglas's total buy and sell value in the current window?

Inside the rolling retention window, Smith Mark Douglas bought $0 and sold $267K based on SEC Form 4 filings.

What was Smith Mark Douglas's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 1,157 JAZZ shares on 2026-06-15, worth $267K, per SEC Form 4 filings.